Co-led CREATE Medicines $122M Series B financing to advance in vivo CAR therapies.
CREATE Medicines is a clinical-stage biotech pioneering in vivo multi-immune programming
CREATE Medicines is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies.